CancerLinQ
CancerLinQ LLC is a not-for-profit subsidiary of the American Society of Clinical Oncology (ASCO) established for the development and operation of the CancerLinQ initiative. With CancerLinQ, ASCO aims to give oncologists a robust quality monitoring system that collects and analyzes data from all patient encounters using Big data enhancing and improving the understanding and treatment of cancer.[1][2]
Platform[edit]
CancerLinQ integrates EHR systems to improve care and fight cancer, bridging this information allows for greater knowledge-sharing and for better research opportunities to cure cancer. Information in a medical record that exists as structured data can be understood by a computer meaning that it can be stored in a database for future retrieval to be manipulated, shared, or transformed via a set of rules or computer instructions, one of the issues with this system is that many types of clinical data are inherently structured such as clinic notes, pathology reports, imaging reports, and cancer stage. Consequently, the electronic health record (EHR) is full of unstructured, free text notes that may accurately reflect the patient journey but are not computable. Current solution to handle important oncology data elements that are critical to understanding basic patient or tumor characteristics is to use teams of “human curators” or manual data abstractors that read and classify these unstructured data. CancerLinQ aims to overcome this issue in the coming years looking for the automation of the database for oncologists.[3][4]
History[edit]
ASCO's board began to research on the use of big data and learning systems with the release of the Institute of Medicine (IoM) report A Foundation for Evidence-Driven Practice: A Rapid-Learning System for Cancer: A Workshop on 2010.[5]
On 2012, prototyde[6] development began and was successfully released on 2013, it included a database of more than 170000 de-identified breast cancer patients from oncology practices around the United States. Data governance and advisory committees were established to advise on design and implementation of the system.
On 2015, SAP and the American Society of Clinical Oncology (ASCO) joined forces to develop the big data software platform that powers CancerlinQ* supported by the data platform SAP HANA, and the data increase every day making CancerlinQ being in a continuous learning process.[7][8]
On 2016, CancerLinQ database surpassed one million patient records. The number of participating practices continues to grow, development and research is ongoing.[7][9]
On 2017, CancerLinQ LLC, announced a long-term partnership with the U.S. Food and Drug Administration (FDA) that will harness cancer patient information and big data analytics to examine the real-world use of emerging and newly approved cancer therapies[10][11]
On 2018, CancerLinQ LLC, has brought on technology collaborators Concerto HealthAI and Tempus to accelerate its joint research effort with the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) aimed at understanding the real-world use, tolerability, and effectiveness of immune checkpoint inhibitors[12][11]
References[edit]
- ↑ Donato, Christine. "Can Big Data Analytics Save Billions in Healthcare Costs?". Forbes. Retrieved 2019-07-15.
- ↑ "CancerLinQ Developing De-Identified Datasets for Quality Improvement". Healthcare Innovation. Retrieved 2019-08-06.
- ↑ "How CancerLinq Improving Physicians Performance". blog.curemd.com. Retrieved 2019-05-02.
- ↑ "CancerLinQ platform challenges & lessons learned after implementation". www.journalofclinicalpathways.com. Retrieved 2019-07-15.
- ↑ Patlak, Margie; Murphy, Sharon (2010). A foundation for evidence-driven practice: a rapid learning system for cancer care: workshop summary. National Academies Press. Unknown parameter
|name-list-style=ignored (help) Search this book on
- ↑ Sledge GW, Hudis CA, Swain SM, Yu PM, Mann JT, Hauser RS, Lichter AS (May 2013). "ASCO's approach to a learning health care system in oncology". Journal of Oncology Practice. 9 (3): 145–8. doi:10.1200/JOP.2013.000957. PMC 3651563. PMID 23942494.
- ↑ 7.0 7.1 Miller RS (October 2016). "CancerLinQ Update". Journal of Oncology Practice. 12 (10): 835–837. doi:10.1200/JOP.2016.014530. PMID 27531380.
- ↑ "SAP Announces SAP® Connected Health Platform and Strategic Relationships for Transforming Healthcare". Castlight Health. Retrieved 2019-08-06.
- ↑ "Database of 1 million patients aims to help inform cancer treatment". STAT. 2017-12-21. Retrieved 2019-08-06.
- ↑ "CancerLinQ Partners with FDA to Study Real-World Use of Newly Approved Cancer Treatments". ASCO. 2017-06-01. Retrieved 2019-04-23.
- ↑ 11.0 11.1 Hinkle, Joe. "CancerLinQ LLC, Concerto HealthAI, and Tempus are Expanding Collaboration with U.S. Food and Drug Administration on Checkpoint Inhibitors". Concerto HealthAI, a SymphonyAI company. Retrieved 2019-08-06.
- ↑ "CancerLinQ LLC, Concerto HealthAI, and Tempus are Expanding Collaboration with U.S. Food and Drug Administration on Checkpoint Inhibitors". ASCO. 2018-08-22. Retrieved 2019-04-23.
External Links[edit]
- ASCO’s CancerLinQ®: Using real-world evidence for discovery:https://www.fda.gov/downloads/Drugs/NewsEvents/UCM592826.pdf
- CancerLinQ infographic
- Official webpage
This article "CancerLinQ" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:CancerLinQ. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
